Brief: Rani Therapeutics Announces Up To $1.085 Billion Collaboration With Chugai Pharmaceutical Co. For Multiple High-Value Therapeutics Including Rare Disease And Immunology Programs And Announces Concurrent Oversubscribed $60.3 Million Financing
17/10/2025 12:32
Oct 17 (Reuters) - Rani Therapeutics Holdings Inc RANI.O: RANI THERAPEUTICS ANNOUNCES UP TO $1.085 BILLION COLLABORATION WITH CHUGAI PHARMACEUTICAL CO. FOR MULTIPLE HIGH-VALUE THERAPEUTICS INCLUDING RARE DISEASE AND IMMUNOLOGY PROGRAMS AND ANNOUNCES CONCURRENT OVERSUBSCRIBED $60.3 MILLION FINANCING RANI THERAPEUTICS HOLDINGS INC - TO RECEIVE $10 MILLION UPFRONT AND UP TO $75 MILLION IN MILESTONES RANI THERAPEUTICS HOLDINGS INC - ANNOUNCES $60.3 MILLION PRIVATE PLACEMENT FINANCING RANI THERAPEUTICS HOLDINGS : CHUGAI HAS OPTION TO EXTEND RIGHTS TO PARTNER WITH CO ON UP TO 5 ADDITIONAL DRUG TARGETS Source text: ID:nGNXbqCxYy Further company coverage: RANI.O
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition